Adjunctive therapy of uncontrolled partial seizures with levetiracetam in Australian patients

Epilepsy and Behavior

Volumn 11, Issue 3, 2007, Pages 338-342

  Somerville, Ernest R ^a   McLaughlin, Daniel B ^b   Robinson, Martin K ^c   Berkovic, Samuel F ^d  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

Adjunctive treatment; Antiepileptic drug; Clinical trial; Levetiracetam; Open label; Partial seizures; Quality of life; Refractory epilepsy

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGED; AGGRESSION; ANTICONVULSANT THERAPY; ANXIETY DISORDER; ARTICLE; AUSTRALIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOCAL EPILEPSY; FREQUENCY ANALYSIS; HUMAN; HYPERAMMONEMIA; INSOMNIA; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; AUSTRIA; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; OXEPINS; PIRACETAM; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 35748936746     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.06.005     Document Type: Article

References (26)

1. Forsgren L., Beghi E., Oun A., and Sillanpaa M. The epidemiology of epilepsy in Europe: a systematic review. Eur J Neurol 12 (2005) 245-253
2. Baker G.A. The psychosocial burden of epilepsy. Epilepsia 43 Suppl 6 (2002) 26-30
3. Schachter S.C. Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Expert Rev Neurother 6 (2006) 111-118
4. Boylan L.S., Flint L.A., Labovitz D.L., et al. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 62 (2004) 258-261
5. Baker G.A., Jacoby A., Buck D., Stalgis C., and Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 38 (1997) 353-362
6. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
7. Perucca E., and Meador K.J. Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl 181 (2005) 30-35
8. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 (2004) 9861-9866
9. Xu T., and Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3 (2001) 691-698
10. Ben-Menachem E., Falter U., and for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
11. Cereghino J.J., Biton V., Abou-Khalil B., et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
12. Shorvon S.D., Lowenthal A., Janz D., Bielen E., Loiseau P., and European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
13. Morrell M.J., Leppik I., French J., et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54 (2003) 153-161
14. Genton P., Sadzot B., Fejerman N., et al. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Acta Neurol Scand 113 (2006) 387-394
15. Lambrechts D.A., Sadzot B., van Paesschen W., et al. Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands. Seizure 15 (2006) 434-442
16. Salas-Puig J., Serratosa J.M., Viteri C., and Gil-Nagel-Rein A. Safety of levetiracetam as adjunctive therapy in epilepsy: the SKATE trial in Spain. Rev Neurol 38 (2004) 1117-1122
17. Steinhoff B.J., Trinka E., and Wieser H.G. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Seizure 14 (2005) 490-496
18. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
19. Cramer J.A., Perrine K., Devinsky O., and Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 37 (1996) 577-582
20. Cramer J.A., Van Hamme G., and Gil-Nagel A. Adjunctive levetiracetam improves quality of life in line with patient priorities in epilepsy. Epilepsia 43 s8 (2004) 348
21. Leppik I., De Rue K., Edrich P., and Perucca E. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience. Epileptic Disord 8 (2006) 118-130
22. Morrell M.J., McLean M.J., Willmore L.J., et al., for the Steps Study Group. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. Seizure 9 (2000) 241-248
23. Meencke H., and Buyle S. Assessment of a dose-response relationship of levetiracetam. Eur J Neurol 13 (2006) 942-946
24. Spilker B., and Segreti A. Validation of the phenomenon of regression of seizure frequency in epilepsy. Epilepsia 25 (1984) 443-449
25. Somerville E.R. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?. Neurology 59 (2002) 79-83
26. Brown E.G., Wood L., and Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999) 109-117